Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07727434

Stress and Anxiety Before Biopsy, After Biopsy Results, and During Treatment in Patients With Suspected Bone or Soft Tissue Cancer

This prospective observational study will follow adults who are scheduled for a clinically indicated biopsy because of a suspected solid tumor involving bone or soft tissue. The period before biopsy, the disclosure of pathology results, and the start of treatment may be associated with changing levels of psychological stress and anxiety.

The purpose of the study is to compare psychological stress and anxiety in the same participants at three points in their care: before biopsy, after the pathology result or diagnosis is explained, and at treatment initiation. The investigators hypothesize that psychological questionnaire scores will differ across these three time points and may be associated with age, sex, disease stage, metastasis status, and treatment type.

Participants will complete the Hospital Anxiety and Depression Scale, Perceived Stress Scale, and Distress Thermometer. The study team will also collect relevant demographic and routine clinical information from medical records. The study will not assign any biopsy, diagnostic procedure, or treatment. All diagnostic and treatment decisions will be made by the treating clinical team as part of routine care.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istanbul University, Istanbul Faculty of Medicine, Department of Orthopedics and Traumatology

Istanbul, 34093, Turkey (Türkiye)

Location status: Recruiting

Location contact

Hilal Aydemir, M.D.

SUB_INVESTIGATOR

Irmak Polat, M.D.

SUB_INVESTIGATOR

Serkan Bayram, M.D.

CONTACT

[email protected]

+90 535 384 1408

Serkan Bayram, M.D.

PRINCIPAL_INVESTIGATOR

Zeynep E. Çalış, M.D.

SUB_INVESTIGATOR

İsmail T. Atasoy, M.D.

SUB_INVESTIGATOR

İsmail Tarık Atasoy, M.D.

CONTACT

[email protected]

+90 534 632 0870

About this study

BIOPSY-STRESS is a single-center, prospective observational cohort study conducted at Istanbul University, Istanbul Faculty of Medicine, Department of Orthopedics and Traumatology, in collaboration with the Department of Psychiatry. Approximately 100 eligible adults who are scheduled for clinically indicated biopsy because of a suspected solid tumor will be recruited consecutively.

Psychological assessments will be performed at three prespecified stages of routine clinical care: before biopsy, after the pathology result or diagnosis has been communicated to the participant, and at treatment initiation. The assessments will include the Hospital Anxiety and Depression Scale, the Perceived Stress Scale, and the Distress Thermometer.

Relevant demographic, clinical, and radiological information will be obtained from routine hospital records, the hospital information management system, the picture archiving and communication system, and patient files. Prespecified clinical variables will include age, sex, disease stage or extent, metastasis status, and treatment type. No additional biopsy, imaging examination, laboratory test, or other invasive procedure will be performed for research purposes. The study will not assign participants to a diagnostic or therapeutic intervention.

The primary objective is to compare within-participant changes in psychological stress and anxiety levels across the pre-biopsy, post-diagnosis, and treatment-initiation assessments. The secondary objective is to identify demographic and clinical factors associated with higher psychological stress or anxiety.

Participant characteristics and questionnaire scores will be summarized using appropriate descriptive statistics. Change across the three assessment points will be evaluated using repeated-measures analysis of variance when the relevant assumptions are satisfied or the Friedman test when those assumptions are not satisfied. Where appropriate, multivariable linear regression or linear mixed-effects models will be used to examine associations between psychological outcomes and prespecified demographic and clinical factors. Effect estimates and 95% confidence intervals will be reported.

Study data will be collected prospectively and stored in coded form with access restricted to authorized study personnel. Participation involves only questionnaires and collection of routine clinical information. Possible research-related burdens include temporary emotional discomfort and fatigue while completing the questionnaires. Participants may pause questionnaire completion or withdraw from the study. Participants with marked anxiety or depressive symptoms, or those who report suicidal ideation, will be referred for same-day psychiatric evaluation in accordance with the study safety plan.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older.
  • Scheduled for biopsy because of a suspected solid tumor.
  • Able to understand and answer the study questionnaires.
  • Able and willing to provide written informed consent before study participation.

Exclusion criteria

  • History of previous malignancy.
  • Current serious psychiatric disorder, including major depressive disorder or psychotic disorder.
  • Cognitive impairment or communication difficulty that prevents valid completion of the study questionnaires.
  • Severe general medical condition or need for emergency intervention that makes study participation inappropriate.

Treatment and study plan

Routine Diagnostic and Treatment Pathway

Other

Observational exposure of interest. Participants undergo clinically indicated biopsy, pathology-result disclosure, and treatment initiation according to routine clinical care. The study does not assign biopsy, imaging, surgery, systemic treatment, radiotherapy, or any other treatment. Research activities consist of psychological questionnaires and collection of routine demographic, clinical, and radiologic data at the prespecified assessment points.

Primary outcomes

  1. Hospital Anxiety and Depression Scale Anxiety Subscale Score Across Three Assessment Points

    Time frame: Within 7 days before biopsy; within 7 days after pathology-result disclosure; and within 7 days before or on the day of treatment initiation, before the first planned treatment.

    Participant-reported anxiety symptoms measured using the Hospital Anxiety and Depression Scale Anxiety subscale. Higher scores indicate greater anxiety symptom burden. Scores will be summarized at each assessment point, and within-participant differences across the three assessment points will be evaluated using prespecified repeated-measures methods.

Secondary outcomes

  1. Hospital Anxiety and Depression Scale Depression Subscale Score Across Three Assessment Points

    Time frame: Within 7 days before biopsy; within 7 days after pathology-result disclosure; and within 7 days before or on the day of treatment initiation, before the first planned treatment.

    Participant-reported depressive symptoms measured using the Hospital Anxiety and Depression Scale Depression subscale. Higher scores indicate greater depressive symptom burden. Scores will be summarized at each assessment point, and within-participant differences across the three assessment points will be evaluated using prespecified repeated-measures methods.

  2. Perceived Stress Scale Total Score Across Three Assessment Points

    Time frame: Within 7 days before biopsy; within 7 days after pathology-result disclosure; and within 7 days before or on the day of treatment initiation, before the first planned treatment.

    Participant-reported perceived stress measured using the Perceived Stress Scale total score. Higher scores indicate greater perceived stress. Scores will be summarized at each assessment point, and within-participant differences across the three assessment points will be evaluated using prespecified repeated-measures methods.

  3. Distress Thermometer Score Across Three Assessment Points

    Time frame: Within 7 days before biopsy; within 7 days after pathology-result disclosure; and within 7 days before or on the day of treatment initiation, before the first planned treatment.

    Global psychological distress measured using the Distress Thermometer, scored from 0 to 10. Higher scores indicate greater distress. Scores will be summarized at each assessment point, and within-participant differences across the three assessment points will be evaluated using prespecified repeated-measures methods.

Study contacts

Contact information is provided by the study sponsor or research team.

Irmak Polat, M.D.

CONTACT

[email protected]

+90 543 773 1949

Serkan Bayram, M.D.

CONTACT

[email protected]

+90 535 384 1408

Sponsors and collaborators

Lead sponsor

Istanbul University

Other

Registry information

Official study title

Comparative Evaluation of Psychological Stress and Anxiety Levels Before Biopsy, After Diagnosis, and During Treatment in Patients With Suspected Primary or Metastatic Bone or Soft Tissue Malignancy

Acronym: BIOPSY-STRESS

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jul 27, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.